Receptor pharmacology of neuroleptics: relation to clinical effects.
This article reviews the receptor pharmacology of neuroleptics, with a focus on newer drugs (e.g., risperidone, olanzapine, sertindole, quetiapine, and ziprasidone) in contrast to older compounds. All these newer compounds are considered to be atypical neuroleptics based upon certain criteria, which are reviewed. Several hypotheses about the molecular mechanisms that explain atypicality are considered. Finally, the in vitro receptor binding data presented for these compounds are related to the therapeutic and adverse effects of these drugs.
Richelson
E
E
Department of Psychiatry, Mayo Clinic and Foundation, Jacksonville, Fla 32224, USA. richel@mayo.edu
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans; D018727:Muscarinic Antagonists / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000187:drug effects; D011976:Receptors, Muscarinic / Q000187:drug effects; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D011985:Receptors, Serotonin / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D018727:Muscarinic Antagonists; D011954:Receptors, Dopamine; D011976:Receptors, Muscarinic; D017981:Receptors, Neurotransmitter; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists